Immunophenotyping of Blast Cells and Immune Effector Cells in Peripheral Whole Blood and Bone Marrow Samples From AML and MDS Patients (AML)

P

Public Assistance-Hospitals of Marseille (AP-HM)

Status

Completed

Conditions

Leukemia

Treatments

Biological: Blood and Marrow sample

Study type

Observational

Funder types

Other

Identifiers

NCT03801005
2018-43

Details and patient eligibility

About

The objective of this study is to evaluate the immune profile of blast cells and immune effector cells in paired peripheral whole blood and bone marrow samples from AML and MDS patients by standardized flow cytometry. A special emphasis will be focused on monitoring expression of CD200 as well as PGP-170 (MDR1) on blasts cells.

Enrollment

38 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age > 18
  • No pregnant woman
  • Patient with myelodysplastic syndrome (with excess blasts) or acute myeloid leukemia
  • Presence of a monitored serum blastose
  • Patient who can obtain free and informed consent (speaks French, no guardianship or curatorship)

Exclusion criteria

  • Minor Patient (< 18 years old)
  • Medical or psychological Condition that could interact with the ability to understand the study,
  • Pregnant or lactating women,
  • Major persons under guardianship or under the protection of justice
  • Persons deprived of their liberty by a judicial or administrative decision
  • Lack of information and opposition to its participation in the study

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems